FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?